{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:42:48Z","timestamp":1772138568162,"version":"3.50.1"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Vifor Fresenius Medical Care Renal Pharma"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hyperkalemia is a common electrolyte disorder that may be rapidly life-threatening because of its cardiac toxicity. Hyperkalemia risk factors are numerous and often combined in the same patient. Most of the strategies to control serum potassium level in the short term have been used for decades. However, evidence for their efficacy and safety remains low. Treatment of hyperkalemia remains challenging, poorly codified, with a risk of overtreatment, including short-term side effects, and with the priority of avoiding unnecessary hospital stays or chronic medication changes. Recently, new oral treatments have been proposed for non-life-threatening hyperkalemia, with encouraging results. Their role in the therapeutic arsenal remains uncertain. Finally, a growing body of evidence suggests that hyperkalemia might negatively impact outcomes in the long term in patients with chronic heart failure or kidney failure through underdosing or withholding of cardiovascular medication (e.g. renin\u2013angiotensin\u2013aldosterone system inhibitors). Recognition of efficacy and potential side effects of treatment may help in tailoring treatments to the patient\u2019s status and conditions. In this review we discuss how treatment of hyperkalemia could be tailored to the patient\u2019s conditions and status, both on the short and mid term.<\/jats:p>","DOI":"10.1093\/ndt\/gfz220","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T04:51:44Z","timestamp":1571115104000},"page":"iii62-iii68","source":"Crossref","is-referenced-by-count":4,"title":["Tailoring treatment of hyperkalemia"],"prefix":"10.1093","volume":"34","author":[{"given":"Maxime","family":"Coutrot","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Critical Care and Burn Unit, Saint-Louis Hospital, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Paris, France"},{"name":"INSERM UMR-S942, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Lariboisi\u00e9re Hospital, Paris, France"},{"name":"University of Paris, Paris Diderot, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"D\u00e9pret","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Critical Care and Burn Unit, Saint-Louis Hospital, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Paris, France"},{"name":"INSERM UMR-S942, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Lariboisi\u00e9re Hospital, Paris, France"},{"name":"University of Paris, Paris Diderot, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Legrand","sequence":"additional","affiliation":[{"name":"INSERM UMR-S942, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Lariboisi\u00e9re Hospital, Paris, France"},{"name":"University of Paris, Paris Diderot, France"},{"name":"Department of Anesthesiology and Peri-Operative Care, University of California, San Francisco, San Francisco, CA, USA"},{"name":"INI-CRCT Network, Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"key":"2019120409205323600_gfz220-B1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.resuscitation.2015.07.017","article-title":"European resuscitation council guidelines for resuscitation 2015","volume":"95","author":"Truhl\u00e1\u0159","year":"2015","journal-title":"Resuscitation"},{"key":"2019120409205323600_gfz220-B2","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/eurheartj\/ehy100","article-title":"Serum potassium and adverse outcomes across the range of kidney function: a CKD prognosis consortium meta-analysis","volume":"39","author":"Kovesdy","year":"2018","journal-title":"Eur Heart J"},{"key":"2019120409205323600_gfz220-B3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000437151","article-title":"Serum potassium, end-stage renal disease and mortality in chronic kidney disease","volume":"41","author":"Nakhoul","year":"2015","journal-title":"Am J Nephrol"},{"key":"2019120409205323600_gfz220-B4","doi-asserted-by":"crossref","first-page":"e0213192","DOI":"10.1371\/journal.pone.0213192","article-title":"Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: a general practice-based, observational study","volume":"14","author":"Jun","year":"2019","journal-title":"PLoS One"},{"key":"2019120409205323600_gfz220-B5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"2019120409205323600_gfz220-B6","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.116.07363","article-title":"Antihypertensive medications and the prevalence of hyperkalemia in a large health system","volume":"67","author":"Chang","year":"2016","journal-title":"Hypertension"},{"key":"2019120409205323600_gfz220-B7","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"2019120409205323600_gfz220-B8","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"2019120409205323600_gfz220-B9","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"2019120409205323600_gfz220-B10","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","article-title":"Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials","volume":"110","author":"Young","year":"2004","journal-title":"Circulation"},{"key":"2019120409205323600_gfz220-B11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the randomized aldactone evaluation study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"2019120409205323600_gfz220-B12","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)","volume":"118","author":"Pitt","year":"2008","journal-title":"Circulation"},{"key":"2019120409205323600_gfz220-B13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2019120409205323600_gfz220-B14","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019120409205323600_gfz220-B15","doi-asserted-by":"crossref","first-page":"e005428","DOI":"10.1161\/JAHA.116.005428","article-title":"Hyperkalemia after initiating renin\u2013angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project","volume":"6","author":"Bandak","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2019120409205323600_gfz220-B16","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/j.1523-1755.2000.00381.x","article-title":"ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group","volume":"58","author":"Bakris","year":"2000","journal-title":"Kidney Int"},{"key":"2019120409205323600_gfz220-B17","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2019120409205323600_gfz220-B18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2215\/CJN.01730215","article-title":"Association between serum potassium and outcomes in patients with reduced kidney function","volume":"11","author":"Luo","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019120409205323600_gfz220-B19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.phrs.2016.09.039","article-title":"Emergency management of severe hyperkalemia: guideline for best practice and opportunities for the future","volume":"113","author":"Rossignol","year":"2016","journal-title":"Pharmacol Res"},{"key":"2019120409205323600_gfz220-B20","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1152\/ajplegacy.1938.124.2.478","article-title":"Electrocardiographic changes and concentration of potassium in serum following intravenous injection of potassium chloride","volume":"124","author":"Winkler","year":"1938","journal-title":"Am J Physiol Legacy Content"},{"key":"2019120409205323600_gfz220-B21","first-page":"235","article-title":"Electrocardiographic changes related to disturbances in potassium metabolism","volume":"73","author":"Burchell","year":"1953","journal-title":"J Lancet"},{"key":"2019120409205323600_gfz220-B22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13613-019-0509-8","article-title":"Management of hyperkalemia in the acutely ill patient","volume":"9","author":"D\u00e9pret","year":"2019","journal-title":"Ann Intensive Care"},{"key":"2019120409205323600_gfz220-B23","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0002-8703(77)80217-2","article-title":"Effects of acute hyperkalemia on cardiac excitability","volume":"94","author":"Lyons","year":"1977","journal-title":"Am Heart J"},{"key":"2019120409205323600_gfz220-B24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.kint.2016.05.015","article-title":"Sodium is the secret re-agent of bicarbonate therapy during hyperkalemia","volume":"90","author":"Robert","year":"2016","journal-title":"Kidney Int"},{"key":"2019120409205323600_gfz220-B25","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/SAP.0000000000001110","article-title":"Lesions associated with calcium gluconate extravasation: presentation of 5 clinical cases and analysis of cases published","volume":"79","author":"Pacheco Compa\u00f1a","year":"2017","journal-title":"Ann Plastic Surg"},{"key":"2019120409205323600_gfz220-B26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jemermed.2008.09.027","article-title":"The effects of intravenous calcium in patients with digoxin toxicity","volume":"40","author":"Levine","year":"2011","journal-title":"J Emerg Med"},{"key":"2019120409205323600_gfz220-B27","doi-asserted-by":"crossref","first-page":"e0154963","DOI":"10.1371\/journal.pone.0154963","article-title":"Optimal dose and method of administration of intravenous insulin in the management of emergency hyperkalemia: a systematic review","volume":"11","author":"Harel","year":"2016","journal-title":"PLoS One"},{"key":"2019120409205323600_gfz220-B28","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/phar.2038","article-title":"A comparison of insulin doses for the treatment of hyperkalemia in patients with renal insufficiency","volume":"37","author":"LaRue","year":"2017","journal-title":"Pharmacotherapy"},{"key":"2019120409205323600_gfz220-B29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/jhm.2545","article-title":"Weight-based insulin dosing for acute hyperkalemia results in less hypoglycemia: hyperkalemia treatment and hypoglycemia","volume":"11","author":"Wheeler","year":"2016","journal-title":"J Hosp Med"},{"key":"2019120409205323600_gfz220-B30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jemermed.2018.12.030","article-title":"Risks of hypoglycemia with insulin therapy for hyperkalemia","volume":"56","author":"Long","year":"2019","journal-title":"J Emerg Med"},{"key":"2019120409205323600_gfz220-B31","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/SLA.0b013e3181f9bb3a","article-title":"Glycemic control and infections in patients with diabetes undergoing noncardiac surgery","volume":"253","author":"King","year":"2011","journal-title":"Ann Surg"},{"key":"2019120409205323600_gfz220-B32","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.amjsurg.2018.12.066","article-title":"Acute hyperglycemia increases sepsis related glycocalyx degradation and endothelial cellular injury: a microfluidic study","volume":"217","author":"Diebel","year":"2019","journal-title":"Am J Surg"},{"key":"2019120409205323600_gfz220-B33","doi-asserted-by":"crossref","first-page":"426","DOI":"10.7326\/0003-4819-110-6-426","article-title":"Nebulized albuterol for acute hyperkalemia in patients on hemodialysis","volume":"110","author":"Allon","year":"1989","journal-title":"Ann Intern Med"},{"key":"2019120409205323600_gfz220-B34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11897-019-00425-2","article-title":"Acute management of hyperkalemia","volume":"16","author":"Liu","year":"2019","journal-title":"Curr Heart Fail Rep"},{"key":"2019120409205323600_gfz220-B35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/cpt1979262181","article-title":"Reduced beta-adrenoceptor sensitivity in the elderly","volume":"26","author":"Vestal","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"2019120409205323600_gfz220-B36","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/jvim.14709","article-title":"Effect of intravenous small-volume hypertonic sodium bicarbonate, sodium chloride, and glucose solutions in decreasing plasma potassium concentration in hyperkalemic neonatal calves with diarrhea","volume":"31","author":"Trefz","year":"2017","journal-title":"J Vet Intern Med"},{"key":"2019120409205323600_gfz220-B37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)31080-8","article-title":"Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial","volume":"392","author":"Jaber","year":"2018","journal-title":"Lancet"},{"key":"2019120409205323600_gfz220-B38","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/ki.2010.315","article-title":"Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics","volume":"79","author":"Pun","year":"2011","journal-title":"Kidney Int"},{"key":"2019120409205323600_gfz220-B39","doi-asserted-by":"crossref","first-page":"264.e9","DOI":"10.1016\/j.amjmed.2012.08.016","article-title":"Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review","volume":"126","author":"Harel","year":"2013","journal-title":"Am J Med"},{"key":"2019120409205323600_gfz220-B40","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2215\/CJN.03640415","article-title":"Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD","volume":"10","author":"Lepage","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019120409205323600_gfz220-B41","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"2019120409205323600_gfz220-B42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"2019120409205323600_gfz220-B43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"2019120409205323600_gfz220-B44","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ehf2.12292","article-title":"Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes\/angiotensin receptor blockers: results from AMETHYST-DN","volume":"5","author":"Pitt","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2019120409205323600_gfz220-B45","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"2019120409205323600_gfz220-B46","doi-asserted-by":"crossref","first-page":"e114686","DOI":"10.1371\/journal.pone.0114686","article-title":"Characterization of structure and function of ZS-9, a K+ selective ion trap","volume":"9","author":"Stavros","year":"2014","journal-title":"PLoS One"},{"key":"2019120409205323600_gfz220-B47","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ki.2014.382","article-title":"A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient","volume":"88","author":"Ash","year":"2015","journal-title":"Kidney Int"},{"key":"2019120409205323600_gfz220-B48","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"key":"2019120409205323600_gfz220-B49","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMc1500353","article-title":"Sodium zirconium cyclosilicate for urgent therapy of severe hyperkalemia","volume":"372","author":"Kosiborod","year":"2015","journal-title":"N Engl J Med"},{"key":"2019120409205323600_gfz220-B50","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2019120409205323600_gfz220-B51","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"2019120409205323600_gfz220-B52","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ejhf.1079","article-title":"Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF: potassium and RAAS inhibitors in HFrEF","volume":"20","author":"Beusekamp","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2019120409205323600_gfz220-B53","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/ejhf.531","article-title":"A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF","volume":"18","author":"Voors","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2019120409205323600_gfz220-B54","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/MAJ.0000000000000475","article-title":"Underprescription of renin-angiotensin system blockers in moderate to severe chronic kidney disease","volume":"349","author":"Shirazian","year":"2015","journal-title":"Am J Med Sci"},{"key":"2019120409205323600_gfz220-B55","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jacc.2012.08.1019","article-title":"Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction","volume":"61","author":"Rassi","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2019120409205323600_gfz220-B56","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12882-019-1228-y","article-title":"The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease","volume":"20","author":"Evans","year":"2019","journal-title":"BMC Nephrol"},{"key":"2019120409205323600_gfz220-B57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.kisu.2016.01.004","article-title":"Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena","volume":"6","author":"Epstein","year":"2016","journal-title":"Kidney Int Suppl"},{"key":"2019120409205323600_gfz220-B58","doi-asserted-by":"crossref","first-page":"e183874","DOI":"10.1001\/jamanetworkopen.2018.3874","article-title":"Association of changes in creatinine and potassium levels after initiation of renin angiotensin aldosterone system inhibitors with emergency department visits, hospitalizations, and mortality in individuals with chronic kidney disease","volume":"1","author":"Garlo","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2019120409205323600_gfz220-B59","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"2019120409205323600_gfz220-B60","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00392-017-1173-3","article-title":"Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications","volume":"107","author":"Legrand","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"2019120409205323600_gfz220-B61","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","article-title":"Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2019120409205323600_gfz220-B62","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2019120409205323600_gfz220-B63","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0735-1097(02)02694-3","article-title":"Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines","volume":"41","author":"Bozkurt","year":"2003","journal-title":"J Am Coll Cardiol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/Supplement_3\/iii62\/31200139\/gfz220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/Supplement_3\/iii62\/31200139\/gfz220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T09:25:48Z","timestamp":1575451548000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/34\/Supplement_3\/iii62\/5652183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":63,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2019,12,4]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfz220","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737033817.793570707","asserted-by":"object"}]},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,12,1]]}}}